• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    7/21/21 2:03:29 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $IMV alert in real time by email
    SC 13G/A 1 eh210170651_13ga1-imv.htm AMENDMENT NO. 1

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    IMV INC.

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    44974L103

    (CUSIP Number)

     

    July 20, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

     

     

    CUSIP No. 44974L103 SCHEDULE 13G Page 2 of 5

     

     

    1

    NAME OF REPORTING PERSON

     

    Fonds de solidarité des travailleurs du Québec (F.T.Q.) (hereinafter referred to as “Fonds”)

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    N/A

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Montreal (Quebec) Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    6,540,104 Common Shares

    6

    SHARED VOTING POWER

     

    N/A

    7

    SOLE DISPOSITIVE POWER

     

    6,540,104 Common Shares

    8

    SHARED DISPOSITIVE POWER

     

    N/A

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,540,104 Common Shares

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    10.15%

     
    12

    TYPE OF REPORTING PERSON

     

    IV

     

     

      

     

     

    CUSIP No. 44974L103 SCHEDULE 13G Page 3 of 5

     

     

    Item 1. (a) Name of Issuer:
         
         IMV INC.
         
      (b) Address of Issuer’s Principal Executive Offices:
         
       

    130 Eileen Stubbs Avenue, suite 19

    Dartmouth, Nova Scotia

    CANADA, B3B 2C4

         
    Item 2. (a) Names of Person Filing:
         
        Fonds de solidarité des travailleurs du Québec (F.T.Q.)

     

      (b) Address of Principal Business Office:
         
        545, Cremazie Blvd. East, suite 200
        Montreal (Quebec) CANADA
        H2M 2W4

     

      (c) Citizenship:
         
        See row 4 of cover page.

     

      (d) Title of Class of Securities:
         
        Common Shares

     

      (e) CUSIP Number:
         
        44974L103

     

    Item 3.    If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
         
        N/A

     

    Item 4.    Ownership.

     

    (a)

    Amount beneficially owned:

     

    8,529,365 Common Shares, including 1,989,261 Common Share purchase warrants exercisable within 60 months of July 20, 2021.

    (b)

    Percent of class:

     

    See row 11 of cover page. The calculation of percentage beneficial ownership is based on 84,070,908 Common Shares, the sum of (1) 82,081,647 Common Shares issued and outstanding based on the Prospectus Supplement filed by IMV INC. on July 15, 2021 and (2) 1,989,261 Common Shares that would result in the event all of the Common Share purchase warrants owned by Fonds were exercised and no other outstanding Common Share purchase warrants were exercised.

     

      

     

     

    CUSIP No. 44974L103 SCHEDULE 13G Page 4 of 5

     

     

    (c) Number of shares as to which the person has:
       
    (i)

    Sole power to vote or to direct the vote:

     

    See row 5 of cover page.

    (ii)

    Shared power to vote or to direct the vote:

     

    See row 6 of cover page.

    (iii)

    Sole power to dispose or to direct the disposition of:

     

    See row 7 of cover page.

    (iv)

    Shared power to dispose or to direct the disposition of:

     

    See row 8 of cover page.

     

    Item 5.   

    Ownership of Five Percent or Less of a Class:

     

    N/A

     

    Item 6.   

    Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

         
    Item 7.   

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

     

    N/A

     

    Item 8.   

    Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9.   

    Notification of Dissolution of Group:

     

    N/A

     

    Item 10.   

    Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

      

     

     

    CUSIP No. 44974L103 SCHEDULE 13G Page 5 of 5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of July 21, 2021.

     

      Fonds de solidarité des travailleurs du Québec (F.T.Q.)  
             
             
     

    By:

    /s/ Liette Leduc  
       

    Liette Leduc

    Senior Director – Legal Affairs

     

     

     

     

     

      

     

     

     

    Get the next $IMV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMV

    DatePrice TargetRatingAnalyst
    9/22/2021$4.00Overweight
    Cantor Fitzgerald
    7/23/2021$14.00Overweight
    Wells Fargo
    More analyst ratings

    $IMV
    SEC Filings

    View All

    SEC Form 15-12G filed by IMV Inc.

    15-12G - IMV Inc. (0001734768) (Filer)

    9/22/23 4:22:10 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:22 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on IMV with a new price target

    Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00

    9/22/21 6:17:21 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Wells Fargo resumed coverage on IMV with a new price target

    Wells Fargo resumed coverage of IMV with a rating of Overweight and set a new price target of $14.00

    7/23/21 7:10:01 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMV Receives NASDAQ Delisting Notice

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote

    5/8/23 4:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available

    5/1/23 12:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Financials

    Live finance-specific insights

    View All

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be

    3/9/23 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

    IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w

    11/10/22 4:05:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IMV Inc.

    SC 13G - IMV Inc. (0001734768) (Subject)

    2/14/23 12:57:14 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    2/3/23 12:06:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    7/21/21 2:03:29 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Leadership Updates

    Live Leadership Updates

    View All

    IMV Inc. Announces Strategic Reorganization

    Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company's Board of Directors and promotion of Brittany Davison to Chief Accounting Officer. "We have m

    9/15/22 7:45:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Announces Annual and Special Meeting of Shareholders Voting Results

    IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the "Meeting"). Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows: Name of nominee Votes FOR % of votes FOR Votes Withheld % of votes Withheld Michael Bailey 27,525,895 99.11% 246,171 0.89% Brittany Davison 27,582,627 99.32% 189,439 0.68%

    6/30/22 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Appoints Andrew Hall as Chief Executive Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. "On behalf of the Board and the Company, I congratulate Andrew on his appointment to the Chief Executive Officer role. Over the last 5 months, Andrew has demonstrated strong leadership and refocused the Company to capitalize on its strengths in immuno-oncology, as well as a strategy designed to fully realize IMV's clear poten

    12/22/21 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care